Boost Your Productivity!Translate documents (Ms-Word, Ms-Excel, ...) faster and better thanks to artificial intelligence!
https://pro.wordscope.com
https://blog. wordscope .com
Eerste hindernis
First-pass

Vertaling van "first developing " (Nederlands → Frans) :

TERMINOLOGIE
IN-CONTEXT TRANSLATIONS
Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s

Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s


FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).

folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.


The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.


Many development projects are progressing toward regulatory submissions in 2010, with up to five in oncology: two additional indications for Afinitor as well as first submissions for the development projects SOM230 (Cushing's disease), LBH589 (Hodgkin's lymphoma) and EPO906 (ovarian cancer).

Des demandes d’autorisation pour de nombreux projets en développement sont en voie d’être déposées en 2010, dont jusqu'à cinq en oncologie : deux indications supplémentaires pour Afinitor ainsi que les projets en développement SOM230 (maladie de Cushing), LBH589 (lymphome de Hodgkin) et EPO906 (cancer des ovaires).


For more results, go to https://pro.wordscope.com to translate your documents with Wordscope Pro!
The report on the Agency’s first year of work was naturally focused on the establishment and transition of the organisation. This second annual report is devoted to the further development of the FAMHP, with a range of examples of the numerous positive activities which perfectly reflect the great diversity of its work.

The report on the Agency’s first year of work was naturally focused on the establishment and transition of the organisation. This second annual report is devoted to the further development of the FAMHP, with a range of examples of the numerous positive activities which perfectly reflect the great diversity of its work.


The first phase in the implementation of a helpdesk in this area has been elaborated and received positive validation from the sector, so that further development work can take place in the course of 2008.

The first phase in the implementation of a helpdesk in this area has been elaborated and received positive validation from the sector, so that further development work can take place in the course of 2008.


During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.

During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.


NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .

NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .


NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .

NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .


The SOE- USE’s first objectives are to train employees in their period of training and to develop an infrastructure that will make cooperation and the exchange of information between members possible.

The SOE- USE’s first objectives are to train employees in their period of training and to develop an infrastructure that will make cooperation and the exchange of information between members possible.




Anderen hebben gezocht naar : eerste hindernis     first-pass     first developing     


datacenter (28): www.wordscope.be (v4.0.br)

'first developing' ->

Date index: 2023-10-22
w